Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent LeasesLiabilities and Shareholders EquityNon-Current AssetsNon-Current Deffered RevenueOperating LeasesOther Non-Current AssetsPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Receivables - OtherRetained EarningsShareholder's EquityTotal Current LiabilitiesTotal LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Avidity Biosciences (RNA) Current Assets: 2019-2025

Historic Current Assets for Avidity Biosciences (RNA) over the last 6 years, with Sep 2025 value amounting to $2.0 billion.

  • Avidity Biosciences' Current Assets rose 21.22% to $2.0 billion in Q3 2025 from the same period last year, while for Sep 2025 it was $2.0 billion, marking a year-over-year increase of 21.22%. This contributed to the annual value of $1.5 billion for FY2024, which is 152.29% up from last year.
  • As of Q3 2025, Avidity Biosciences' Current Assets stood at $2.0 billion, which was up 57.21% from $1.3 billion recorded in Q2 2025.
  • Avidity Biosciences' Current Assets' 5-year high stood at $2.0 billion during Q3 2025, with a 5-year trough of $287.3 million in Q2 2021.
  • For the 3-year period, Avidity Biosciences' Current Assets averaged around $1.1 billion, with its median value being $1.3 billion (2025).
  • In the last 5 years, Avidity Biosciences' Current Assets decreased by 18.80% in 2021 and then surged by 191.97% in 2024.
  • Over the past 5 years, Avidity Biosciences' Current Assets (Quarterly) stood at $411.1 million in 2021, then spiked by 51.52% to $622.9 million in 2022, then dropped by 1.87% to $611.3 million in 2023, then skyrocketed by 152.29% to $1.5 billion in 2024, then increased by 21.22% to $2.0 billion in 2025.
  • Its last three reported values are $2.0 billion in Q3 2025, $1.3 billion for Q2 2025, and $1.4 billion during Q1 2025.